29 Jun REFILE-Novartis chairman says Alcon worth $20 bln-$30 bln – Finanz und Wirtschaft
ZURICH, June 30 (Reuters) – The chairman of Swiss drugmaker
Novartis expects Alcon to be valued at between $20
billion and $30 billion when the opthalmic devices unit is spun
off to shareholders next year, he said in an interview with
Finanz und Wirtschaft.
“Just how much it’s ultimately going to be will be determined
when we know how debt and other things will be quantified,”
Joerg Reinhardt told the Swiss financial newspaper.
Novartis expects Alcon to be valued at between $20
billion and $30 billion when the opthalmic devices unit is spun
off to shareholders next year, he said in an interview with
Finanz und Wirtschaft.
“Just how much it’s ultimately going to be will be determined
when we know how debt and other things will be quantified,”
Joerg Reinhardt told the Swiss financial newspaper.
Sorry, the comment form is closed at this time.